Oregon Therapeutics & Lantern Pharma Launch Strategic AI Collaboration to Optimize Development of First-In-Class Drug Candidate XCE853 – A Potent Inhibitor of Cancer Metabolism [Yahoo! Fin...
Lantern Pharma Inc. (LTRN)
Company Research
Source: Yahoo! Finance
solid and hematological cancers, and is ready to advance to Investigational New Drug (IND)-enabling development. The AI-enabled collaboration aims to refine and expand the positioning of XCE853, a novel protein disulfide isomerase (PDI) inhibitor, in new and targeted oncology indications, including for drug-resistant tumors. The collaboration is leveraging RADR ® 's AI-based capabilities, including 200+ machine learning (ML) algorithms and foundational models for oncology drug development to uncover biomarkers and molecular correlates of efficacy and define potential combination regimens to sharpen XCE853's drug development strategy. Lantern Pharma is receiving equal IP co-ownership and drug development rights in newly discovered biomarkers, novel indications, and use for new pharmacological strategies for XCE853. PARIS & DALLAS, May 06, 2024 BUSINESS WIRE Lantern Pharma Inc . (NASDAQ: LTRN), a leading artificial intelligence (AI) oncology drug discovery and development compan
Show less
Read more
Impact Snapshot
Event Time:
LTRN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LTRN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LTRN alerts
High impacting Lantern Pharma Inc. news events
Weekly update
A roundup of the hottest topics
LTRN
News
- Lantern Pharma Reports First Quarter 2024 Financial Results and Business Highlights [Yahoo! Finance]Yahoo! Finance
- Lantern Pharma Reports First Quarter 2024 Financial Results and Business HighlightsBusiness Wire
- Lantern Pharma and Oregon partner to develop cancer treatment [Yahoo! Finance]Yahoo! Finance
- Oregon Therapeutics & Lantern Pharma Launch Strategic AI Collaboration to Optimize Development of First-In-Class Drug Candidate XCE853 – A Potent Inhibitor of Cancer MetabolismBusiness Wire
- Lantern Pharma to Report First Quarter 2024 Operating & Financial Results on May 9th, 2024 at 4:30 p.m. ET [Yahoo! Finance]Yahoo! Finance
LTRN
Earnings
- 5/9/24 - Miss
LTRN
Analyst Actions
- 4/25/24 - HC Wainwright
LTRN
Sec Filings
- 5/9/24 - Form 8-K
- 5/9/24 - Form 10-Q
- 5/3/24 - Form ARS
- LTRN's page on the SEC website